<p>加利福尼亚州瓦伦西亚，2026 年 2 月 13 日（全球新闻通讯）—— AVITA Medical, Inc.（ASX: AVH，NASDAQ: RCEL），一家领先的急性创伤护理公司，提供变革性解决方案，邀请股东和潜在投资者参加其投资者网络研讨会，由临时首席执行官 Cary Vance 和首席财务官 David O’Toole 于 2026 年 2 月 18 日下午 2:00（太平洋标准时间）（2026 年 2 月 19 日上午 9:00，澳大利亚东部夏令时间）进行简报和演示。</p>
<p>网络研讨会的演示将涵盖 AVITA Medical 最近的 2025 财年第四季度和全年财务及业务结果，并以问答环节结束。参与者被邀请通过注册页面提交他们的问题。</p>
<p>要注册参加演示，请点击此 Zoom 链接：</p>
<p>https://us06web.zoom.us/webinar/register/WN_F_ldbJWLS1SQqUKIjfwFWQ</p>
<p>重播将在 AVITA Medical 网站上提供，网址为：https://ir.avitamedical.com/</p>
<p><strong>关于 AVITA Medical, Inc.</strong></p>
<p>AVITA Medical®是一家领先的急性创伤护理公司，提供变革性解决方案。我们的技术旨在优化伤口愈合，有效加速患者恢复的时间。我们平台的核心是 RECELL®，已获得 FDA 批准用于治疗热烧伤和创伤性伤口。RECELL 利用患者自身皮肤的愈合特性，创造出喷雾皮肤™，为改善临床结果提供创新解决方案。在美国，AVITA Medical 还拥有制造、营销、销售和分销 PermeaDerm®（一种生物合成伤口基质）的独家权利，以及营销、销售和分销 Cohealyx™（AVITA Medical 品牌的胶原基真皮基质）的独家权利。</p>
<p>在国际市场上，RECELL 已获批准用于促进广泛应用的皮肤愈合，包括热烧伤和创伤性伤口。RECELL 和 RECELL GO®已在欧洲获得 CE 标志；RECELL 在澳大利亚注册为 TGA，并在日本获得 PMDA 批准。</p>
<p>要了解更多信息，请访问 www.avitamedical.com。</p>
<p><strong>投资者与媒体联系：</strong></p>
<p>Ben Atkins</p>
<p>电话 +1-805 341 1571</p>
<p>investor@avitamedical.com</p>
<p>media@avitamedical.com</p>
<p>经 AVITA Medical, Inc.首席财务官授权发布。</p>
<p>©2026 AVITA Medical。AVITA Medical®、Cohealyx®、RECELL®、RECELL GO®和喷雾皮肤 TM 是 AVITA Medical 的商标。PermeaDerm®是 Stedical Scientific, Inc.拥有的注册商标。所有其他商标均为其各自所有者的财产。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5ETTJOU00zTkRJMU1UVTJJekl4T0RFMU1UQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5ETTJOU00zTkRJMU1UVTJJekl4T0RFMU1UQT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2MzNTMyMDYtMmJjYS00N2JiLWFiNWYtNDQ5M2E4ZTk0MGI4LTExOTMwNzktMjAyNi0wMi0xMy1lbg==/tiny/AVITA-Medical.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2MzNTMyMDYtMmJjYS00N2JiLWFiNWYtNDQ5M2E4ZTk0MGI4LTExOTMwNzktMjAyNi0wMi0xMy1lbg==/tiny/AVITA-Medical.png"/></p>

RCEL

<p>AVITA Medical, Inc. 将于 2026 年 2 月 18 日下午 2:00（太平洋标准时间）举办投资者网络研讨会，届时将有临时首席执行官 Cary Vance 和首席财务官 David O’Toole 出席。会议将讨论公司 2025 年第四季度和全年财务业绩，随后进行问答环节。参与者可以通过提供的 Zoom 链接进行注册。AVITA Medical 专注于急性创伤护理解决方案，包括获得 FDA 批准的用于皮肤愈合的 RECELL 技术</p>

<p>VALENCIA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2026, at 2:00 p.m. Pacific Standard Time (February 19, 2026, at 9:00 a.m. Australian Eastern Daylight Time).</p>
<div class="lb-trans"><p>加利福尼亚州瓦伦西亚，2026 年 2 月 13 日（全球新闻通讯）—— AVITA Medical, Inc.（ASX: AVH，NASDAQ: RCEL），一家领先的急性创伤护理公司，提供变革性解决方案，邀请股东和潜在投资者参加其投资者网络研讨会，由临时首席执行官 Cary Vance 和首席财务官 David O’Toole 于 2026 年 2 月 18 日下午 2:00（太平洋标准时间）（2026 年 2 月 19 日上午 9:00，澳大利亚东部夏令时间）进行简报和演示。</p>
</div><p>The webinar presentation will cover financial and business results from AVITA Medical’s recent fourth-quarter and full-year 2025 earnings webcast and will conclude with a Q&amp;A session. Participants are invited to submit their questions via the registration page.</p>
<div class="lb-trans"><p>网络研讨会的演示将涵盖 AVITA Medical 最近的 2025 财年第四季度和全年财务及业务结果，并以问答环节结束。参与者被邀请通过注册页面提交他们的问题。</p>
</div><p>To register for the presentation, please follow this Zoom link:</p>
<div class="lb-trans"><p>要注册参加演示，请点击此 Zoom 链接：</p>
</div><p>https://us06web.zoom.us/webinar/register/WN_F_ldbJWLS1SQqUKIjfwFWQ</p>
<div class="lb-trans"><p>https://us06web.zoom.us/webinar/register/WN_F_ldbJWLS1SQqUKIjfwFWQ</p>
</div><p>A replay will be available on the AVITA Medical website at: https://ir.avitamedical.com/</p>
<div class="lb-trans"><p>重播将在 AVITA Medical 网站上提供，网址为：https://ir.avitamedical.com/</p>
</div><p><strong>About AVITA Medical, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 AVITA Medical, Inc.</strong></p>
</div><p>AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.</p>
<div class="lb-trans"><p>AVITA Medical®是一家领先的急性创伤护理公司，提供变革性解决方案。我们的技术旨在优化伤口愈合，有效加速患者恢复的时间。我们平台的核心是 RECELL®，已获得 FDA 批准用于治疗热烧伤和创伤性伤口。RECELL 利用患者自身皮肤的愈合特性，创造出喷雾皮肤™，为改善临床结果提供创新解决方案。在美国，AVITA Medical 还拥有制造、营销、销售和分销 PermeaDerm®（一种生物合成伤口基质）的独家权利，以及营销、销售和分销 Cohealyx™（AVITA Medical 品牌的胶原基真皮基质）的独家权利。</p>
</div><p>In international markets, RECELL is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. RECELL and RECELL GO® have received the CE mark in Europe; and RECELL is TGA-registered in Australia, and has PMDA approval in Japan.</p>
<div class="lb-trans"><p>在国际市场上，RECELL 已获批准用于促进广泛应用的皮肤愈合，包括热烧伤和创伤性伤口。RECELL 和 RECELL GO®已在欧洲获得 CE 标志；RECELL 在澳大利亚注册为 TGA，并在日本获得 PMDA 批准。</p>
</div><p>To learn more, visit www.avitamedical.com.</p>
<div class="lb-trans"><p>要了解更多信息，请访问 www.avitamedical.com。</p>
</div><p><strong>Investor &amp; Media Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者与媒体联系：</strong></p>
</div><p>Ben Atkins</p>
<div class="lb-trans"><p>Ben Atkins</p>
</div><p>Phone +1-805 341 1571</p>
<div class="lb-trans"><p>电话 +1-805 341 1571</p>
</div><p>investor@avitamedical.com</p>
<div class="lb-trans"><p>investor@avitamedical.com</p>
</div><p>media@avitamedical.com</p>
<div class="lb-trans"><p>media@avitamedical.com</p>
</div><p>Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.</p>
<div class="lb-trans"><p>经 AVITA Medical, Inc.首席财务官授权发布。</p>
</div><p>©2026 AVITA Medical. AVITA Medical®, Cohealyx®, RECELL®, RECELL GO®, and Spray-On SkinTM are trademarks of AVITA Medical. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.</p>
<div class="lb-trans"><p>©2026 AVITA Medical。AVITA Medical®、Cohealyx®、RECELL®、RECELL GO®和喷雾皮肤 TM 是 AVITA Medical 的商标。PermeaDerm®是 Stedical Scientific, Inc.拥有的注册商标。所有其他商标均为其各自所有者的财产。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU5ETTJOU00zTkRJMU1UVTJJekl4T0RFMU1UQT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY1NDM2NSM3NDI1MTU2IzIxODE1MTA="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2MzNTMyMDYtMmJjYS00N2JiLWFiNWYtNDQ5M2E4ZTk0MGI4LTExOTMwNzktMjAyNi0wMi0xMy1lbg==/tiny/AVITA-Medical.png" alt="" original-src="https://ml.globenewswire.com/media/M2MzNTMyMDYtMmJjYS00N2JiLWFiNWYtNDQ5M2E4ZTk0MGI4LTExOTMwNzktMjAyNi0wMi0xMy1lbg==/tiny/AVITA-Medical.png"/></p>

AVITA Medical 将举办投资者网络研讨会简报 | RCEL 股票新闻